Global MRD (Minimal Residual Disease) Testing Research Report 2023: Rising Number of Clinical Trials in Prolonged MRD-Negative Treatment Decisions Present Opportunities

Dublin, July 21, 2023 (GLOBE NEWSWIRE) -- The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to's offering.

The global MRD testing market is projected to reach $6.67 billion by 2033 from $1.47 billion in 2022, growing at a CAGR of 14.81% during the forecast period 2023-2033.

The MRD testing market is witnessing significant growth driven by expanding Medicare coverage, increased consumer awareness, and the integration of MRD testing into clinical practice.

As the demand for accurate and sensitive methods to monitor and manage cancer patients rises, technologies such as PCR, NGS, and flow cytometry play a crucial role in detecting and quantifying minimal residual disease.

With its clinical significance and potential for personalized treatment approaches, the MRD testing market presents substantial opportunities for diagnostic companies, pharmaceutical manufacturers, and research institutions to develop innovative solutions.

Efforts to enhance the sensitivity, accuracy, and efficiency of MRD testing have led to advancements in technology, laboratory protocols, and novel approaches, contributing to improved patient outcomes and survival rates in the fight against cancer.

Market Segmentation

Flow Cytometry to Continue its Dominance as Leading Technology Segment

The global MRD testing market is led by flow cytometry in the technology segment, with a 41.14% share in 2022. The market growth is attributed to recent technological innovations in multiparametric flow cytometry, such as the development of high-sensitivity 10-color and 12-color flow cytometry assay for the identification of leukemia-associated phenotypes (LAPs) and estimation of the prognostic significance of treatment in MRD patients.

MRD testing uses highly sensitive methods such as flow cytometry, PCR, NGS, and other methods. These tests use bone marrow samples and/or peripheral blood cells (taken through a vein). Significant advancements are being witnessed in the development of highly sensitive, quantitative, and multiplex assays.

Some of the new technologies include NGS and low-cost PCR devices available in the form of multiparameter assays and multiplexing devices for MRD testing. Techniques such as karyotyping and classical microscopy have lesser value in MRD detection due to their low sensitivity.

Solid Tumor-Based Target Detection to Witness the Highest Growth between 2023 and 2033

The global MRD testing market is estimated to be led by the solid tumor in the target detection segment, with a share of 15.09% in 2022, owing to the increasing number of companies entering the market with a focus on solid tumor based MRD testing. The assessment of minimal residual disease (MRD) is a crucial prognostic indicator, and the application of circulating tumor DNA (ctDNA) analysis for evaluating MRD in solid tumors after curative treatment and prior to disease recurrence has shown great therapeutic potential. This promising advancement is a key driving force behind the growth of ctDNA analysis in the field.

Hospitals and Speciality Clinics to Witness the Highest Growth between 2023 and 2033

The global MRD testing market is estimated to be led by the hospitals and specialty clinics in the end user segment, with a share of 44.38% in 2022. Hospitals are at the forefront of providing MRD testing kits and services to detect residual cells in solid tumors and hematological malignancies in routine healthcare procedures. There is high adoption of various testing assays by hospitals, particularly in the field of oncology.

Moreover, hospitals, particularly in leading regions such as North America and Europe, and also to a certain extent in Asia-Pacific (APAC), have incorporated extensive molecular diagnostics test portfolios to provide superior care to patients. Other end users, such as outpatient clinics and cancer clinics, also contribute significantly to the global MRD testing market.

Regional Analysis

North America's minimal residual disease testing market is expected to reach $2.75 billion in 2033 and is currently the leading contributor to the market.

The rising incidence of hematological malignancies such as leukemia and lymphoma, coupled with the development of innovative tests, are key factors that contribute to North America's dominance in the global MRD testing market. However, the Asia-Pacific region, constituting several emerging economies, is expected to register the highest CAGR of 16.06% during the forecast period 2023-2033.

Competitive Strategies

Key players in the MRD testing market analyzed and profiled in the study involve major residual testing-based companies and test manufacturers.

Moreover, a detailed competitive benchmarking of the players operating in the MRD testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The top segment players leading in the market include 11 public companies that capture around 73.33% of the presence in the market. On the other hand, there are four private players, including Invivoscribe, Inc. and Mission Bio, among others, which account for approximately 26.67% of the presence in the market.

Recent Developments in the MRD Testing Market

  • In April 2023, Quest Diagnostics acquired Haystack Oncology, expanding its oncology portfolio with the inclusion of advanced liquid biopsy technology. This addition aimed to enhance personalized cancer care by offering highly sensitive diagnostic capabilities.
  • In April 2023, Integrated DNA Technologies launched the Archer FUSIONPlex Core Solid Tumor Panel, a pioneering cancer research testing solution that has been enhanced and fine-tuned to include a broader range of single nucleotide variant (SNV) and indel coverage.
  • In April 2023, Adaptive Biotechnologies collaborated on a translational partnership with Takeda to employ its clonoSEQ assay throughout Takeda's range of hematologic malignancy treatments, enabling the measurement of minimal residual disease.

Key Attributes:

Report AttributeDetails
No. of Pages214
Forecast Period2023 - 2033
Estimated Market Value (USD) in 2023$1.68 Billion
Forecasted Market Value (USD) by 2033$6.67 Billion
Compound Annual Growth Rate14.8%
Regions CoveredGlobal

Key Companies Profiled:

  • Adaptive Biotechnologies
  • ARUP Laboratories
  • Bio-Rad Laboratories, Inc.
  • Cergentis B.V.
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc.
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Mission Bio, Inc.
  • ICON plc
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • OPKO Health, Inc.
  • Quest Diagnostics Incorporated
  • Sysmex Corporation

Market Dynamics

Market Drivers

  • Advent of MRD Testing and its Awareness among Consumers
  • Increasing Incidence of Cancer Cases Demanding MRD Testing
  • Rise in Administration of Solid Tumor Diagnosis in MRD Testing Ecosystem
  • Expanding Medicare Coverage for MRD Testing

Market Challenges

  • Early-Risk of Progression and Relapse due to MRD Negative Results
  • Substantially High Cost of MRD Testing

Market Opportunities

  • Advancements in the Development of Companion Diagnostics
  • Rising Number of Clinical Trials in Prolonged MRD-Negative Treatment Decisions

Industry Insights

Legal and Regulatory Framework of MRD Tests

  • U.S.
  • Europe
  • Asia-Pacific

Reimbursement Scenario

  • North America
  • European Union
  • Asia-Pacific

Supply Chain Analysis

  • For Laboratory Developed Tests (LDTs)
  • For In-Vitro Diagnostics (IVDs)

Market Overview

  • MRD Testing Workflow Analysis
  • MRD Testing: Solid Tumor vs. Hematological Malignancy
  • Evolution of MRD Testing
  • Market Footprint
  • Market Size and Future Growth Potential

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Global MRD Testing Market

Contact Data